The MHRA (UK) and FDA (USA) are moving toward a more integrated regulatory cooperation model, aligning evaluation standards and leveraging mutual reliance mechanisms to reduce duplication and support quicker cross-border access to innovative medical technologies, particularly AI-enabled solutions.